

# The Gulf War era multiple sclerosis cohort: age and inci service

Brain

135, 1778-1785

DOI: [10.1093/brain/aws099](https://doi.org/10.1093/brain/aws099)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Environmental Risk Factors for Multiple Sclerosis: A Review with a Focus on Molecular Mechanisms. International Journal of Molecular Sciences, 2012, 13, 11718-11752.	1.8	166
2	An unchanging man faced with changing times. Brain, 2012, 135, 1663-1665.	3.7	3
3	The initiation and prevention of multiple sclerosis. Nature Reviews Neurology, 2012, 8, 602-612.	4.9	253
4	Role of puberty in multiple sclerosis risk and course. Clinical Immunology, 2013, 149, 192-200.	1.4	64
5	Environmental factors in multiple sclerosis. Expert Review of Neurotherapeutics, 2013, 13, 3-9.	1.4	229
6	Incidence of Scleritis and Episcleritis: Results From the Pacific Ocular Inflammation Study. American Journal of Ophthalmology, 2013, 156, 752-758.e3.	1.7	37
7	Sexual disparities in the incidence and course of MS. Clinical Immunology, 2013, 149, 201-210.	1.4	81
9	Epidemiology in multiple sclerosis: a pilgrimâ€™s progress. Brain, 2013, 136, 2904-2917.	3.7	33
10	Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology, 2013, 80, 1734-1739.	1.5	218
11	Hospitalization Rates and Discharge Status in Multiple Sclerosis. Multiple Sclerosis International, 2013, 2013, 1-7.	0.4	18
12	Sex and gender issues in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2013, 6, 237-248.	1.5	368
13	Suicidal Behavior and Neurological Illnesses. Journal of Depression & Anxiety, 2013, 02, .	0.1	9
14	Take Home Points. , 2014, , 216-217.		1
15	Is it time for a new global classification of multiple sclerosis?. Journal of the Neurological Sciences, 2014, 344, 171-181.	0.3	66
16	Russell W Brain and the aetiology of multiple sclerosis--a historical perspective. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 423-427.	0.2	3
17	Multiple Sclerosis in Gulf War Era Veterans. 2. Military Deployment and Risk of Multiple Sclerosis in the First Gulf War. Neuroepidemiology, 2014, 42, 226-234.	1.1	13
18	Incidence of Multiple Sclerosis and Related Disorders in Asian Populations of British Columbia. Canadian Journal of Neurological Sciences, 2015, 42, 235-241.	0.3	11
19	Hormonal and gender-related immune changes in multiple sclerosis. Acta Neurologica Scandinavica, 2015, 132, 62-70.	1.0	51

#	ARTICLE	IF	CITATIONS
20	Immunogenetics of Neurological Disease. , 2015, , 39-50.		0
21	VHA Multiple Sclerosis Surveillance Registry and its similarities to other contemporary multiple sclerosis cohorts. Journal of Rehabilitation Research and Development, 2015, 52, 263-272.	1.6	16
22	Genomewide admixture study in Mexican Mestizos with multiple sclerosis. Clinical Neurology and Neurosurgery, 2015, 130, 55-60.	0.6	20
23	Genetic determinants of risk and progression in multiple sclerosis. Clinica Chimica Acta, 2015, 449, 16-22.	0.5	32
24	The immunogenetics of multiple sclerosis: A comprehensive review. Journal of Autoimmunity, 2015, 64, 13-25.	3.0	301
25	An ImmunoChip study of multiple sclerosis risk in African Americans. Brain, 2015, 138, 1518-1530.	3.7	60
26	Multiple sclerosis in US minority populations. Neurology: Clinical Practice, 2015, 5, 132-142.	0.8	94
27	Sex-Based Differences in Multiple Sclerosis (MS): Part II: Rising Incidence of Multiple Sclerosis in Women and the Vulnerability of Men to Progression of this Disease. Current Topics in Behavioral Neurosciences, 2015, 26, 57-86.	0.8	38
28	Retinal damage and vision loss in African American multiple sclerosis patients. Annals of Neurology, 2015, 77, 228-236.	2.8	53
29	EBV and Autoimmunity. Current Topics in Microbiology and Immunology, 2015, 390, 365-385.	0.7	99
30	Burden of Neurological Disease. , 2015, , 748-764.		0
31	Genetics of Multiple Sclerosis. , 2016, , 45-54.		2
32	Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Annals of Neurology, 2016, 79, 178-189.	2.8	45
33	Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic Americans. Journal of Child Neurology, 2016, 31, 1068-1073.	0.7	18
34	Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update. Seminars in Neurology, 2016, 36, 103-114.	0.5	209
35	European multiple sclerosis risk variants in the south Asian population. Multiple Sclerosis Journal, 2016, 22, 1536-1540.	1.4	15
36	The killer immunoglobulin-like receptor KIR3DL1 in combination with HLA-Bw4 is protective against multiple sclerosis in African Americans. Genes and Immunity, 2016, 17, 199-202.	2.2	29
37	Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania. Journal of Neurology, 2016, 263, 792-798.	1.8	11

#	ARTICLE	IF	CITATIONS
38	Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 684-695.	1.0	24
39	Multiple sclerosis in men: management considerations. <i>Journal of Neurology</i> , 2016, 263, 1263-1273.	1.8	30
40	Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. <i>Cortex</i> , 2016, 74, 449-475.	1.1	326
41	Ethnicity and prevalence of multiple sclerosis in east London. <i>Multiple Sclerosis Journal</i> , 2017, 23, 36-42.	1.4	54
42	Adjustment modes in the trajectory of progressive multiple sclerosis: a qualitative study and conceptual model. <i>Psychology and Health</i> , 2017, 32, 343-360.	1.2	13
43	Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database. <i>Clinical and Experimental Neuroimmunology</i> , 2017, 8, 318-326.	0.5	20
44	The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. <i>Trends in Genetics</i> , 2017, 33, 960-970.	2.9	165
45	Five-Year Safety Data for More than 55,000 Subjects following Breast Implantation: Comparison of Rare Adverse Event Rates with Silicone Implants versus National Norms and Saline Implants. <i>Plastic and Reconstructive Surgery</i> , 2017, 140, 666-679.	0.7	46
46	MS in self-identified Hispanic/Latino individuals living in the US. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731772510.	0.5	9
47	Multiple Sclerosis in Latin Americans: Genetic Aspects. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 57.	2.0	14
48	Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. <i>Journal of Medical Economics</i> , 2017, 20, 228-238.	1.0	17
49	An Evidence Map of the Women Veteransâ€™ Health Research Literature (2008â€“2015). <i>Journal of General Internal Medicine</i> , 2017, 32, 1359-1376.	1.3	60
50	Multiple Sclerosis; <i>Epidemiology</i> , 2017, , ,		1
51	Multiple Sclerosis Mortality by Race/Ethnicity, Age, Sex, and Time Period in the United States, 1999â€“2015. <i>Neuroepidemiology</i> , 2018, 50, 35-40.	1.1	36
52	Lower prevalence of multiple sclerosis in First Nations Canadians. <i>Neurology: Clinical Practice</i> , 2018, 8, 33-39.	0.8	6
53	Temporal trends in multiple sclerosis prevalence and incidence in a large population. <i>Neurology</i> , 2018, 90, e1435-e1441.	1.5	60
54	Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate. <i>Current Medical Research and Opinion</i> , 2018, 34, 107-115.	0.9	14
55	The Gulf War era multiple sclerosis cohort: 3. Early clinical features. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 76-84.	1.0	6

#	ARTICLE	IF	CITATIONS
56	Ethnic Considerations and Multiple Sclerosis Disease Variability in the United States. <i>Neurologic Clinics</i> , 2018, 36, 151-162.	0.8	36
57	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1362-1371.	1.7	20
58	Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence. <i>Psychopharmacology</i> , 2018, 235, 3303-3313.	1.5	17
59	Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. <i>Brain</i> , 2018, 141, 3115-3129.	3.7	67
60	Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis. <i>Journal of Neuroscience Research</i> , 2018, 96, 1831-1846.	1.3	8
61	Salivary biomarkers for the diagnosis and monitoring of neurological diseases. <i>Biomedical Journal</i> , 2018, 41, 63-87.	1.4	122
62	Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. <i>Pharmacoeconomics</i> , 2018, 36, 1223-1252.	1.7	16
63	Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 157-174.	0.9	12
64	MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. <i>Nutrients</i> , 2018, 10, 268.	1.7	58
65	Association between Allelic Variants of IL2, IL2RA, and IL7R Genes and Multiple Sclerosis. <i>Russian Journal of Genetics</i> , 2019, 55, 487-494.	0.2	4
66	Cord-AGE-Gender Connections Shape the Pathophysiology of Multiple Sclerosis Progressive Forms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5103.	1.8	2
67	Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2019, 18, 983-985.	4.9	1
68	Unmasking the Masquerader: A Delayed Diagnosis of MS and Its 4.5% Years of Implications in an Older African American Male. <i>Case Reports in Medicine</i> , 2019, 2019, 1-5.	0.3	2
69	Unraveling susceptibility to multiple sclerosis. <i>Science</i> , 2019, 365, 1383-1384.	6.0	7
70	Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 269-285.	4.9	716
71	Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. <i>Frontiers in Endocrinology</i> , 2019, 10, 265.	1.5	111
72	A novel comprehensive paradigm for the etiopathogenesis of multiple sclerosis: therapeutic approaches and future perspectives on its treatment. <i>Amino Acids</i> , 2019, 51, 745-759.	1.2	17
73	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.5	765

#	ARTICLE	IF	CITATIONS
74	Validation of an algorithm for identifying MS cases in administrative health claims datasets. <i>Neurology</i> , 2019, 92, e1016-e1028.	1.5	69
75	Epstein-Barr Virus in Multiple Sclerosis. , 2019, , .		1
76	Comment on "US FDA Breast Implant Postapproval Studies: Long-term Outcomes in 99,993 Patients" <i>Annals of Surgery</i> , 2019, 270, e55-e57.	2.1	3
77	US FDA Breast Implant Postapproval Studies. <i>Annals of Surgery</i> , 2019, 269, 30-36.	2.1	205
78	The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1329-1339.	1.4	23
79	Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1948-1952.	1.4	25
80	Siponimod and CYP2C9 Allele Prevalence Among Blacks. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 429-431.	1.0	5
81	Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race. <i>Autoimmunity Reviews</i> , 2020, 19, 102423.	2.5	68
82	Two genetic variants explain the association of European ancestry with multiple sclerosis risk in African-Americans. <i>Scientific Reports</i> , 2020, 10, 16902.	1.6	10
83	Feasibility of "Sit Less, Move More": An intervention for reducing sedentary behavior Among African Americans with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732093234.	0.5	4
84	Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective Analysis. <i>Biomedicine</i> , 2020, 8, 534.	1.4	7
85	Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020, 30, 342-350.	1.0	12
86	Psycho-neuro-endocrino-immunologic issues in multiple sclerosis: a critical review of clinical and therapeutic implications. <i>Hormones</i> , 2020, 19, 485-496.	0.9	12
87	CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 43.	1.8	22
88	Natural killer cells in multiple sclerosis: A review. <i>Immunology Letters</i> , 2020, 222, 1-11.	1.1	34
89	Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101959.	0.9	20
90	Race and ethnicity on MS presentation and disease course. <i>Multiple Sclerosis Journal</i> , 2020, 26, 561-567.	1.4	78
91	Physical activity and peak oxygen consumption are associated with walking in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101941.	0.9	5

#	ARTICLE	IF	CITATIONS
92	Prevalence and incidence of multiple sclerosis in Ardabil, Northwest of Iran. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102605.	0.9	6
93	Epidemiology of Multiple Sclerosis and Environmental Risk Factors. , 2021, , 137-153.		0
95	Perceptions and Preferences Regarding Multiple Sclerosis Research Among Racial and Ethnic Groups. <i>International Journal of MS Care</i> , 2021, 23, 170-177.	0.4	15
96	Progress in progestin-based therapies for neurological disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 122, 38-65.	2.9	20
97	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. <i>Frontiers in Neurology</i> , 2021, 12, 554375.	1.1	18
98	How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity. <i>Neurology: Clinical Practice</i> , 2021, 11, 335-341.	0.8	25
99	Ethnicity and multiple sclerosis - moving beyond preconceptions. <i>Advances in Clinical Neuroscience &amp; Rehabilitation: ACNR</i> , 0, 20, .	0.1	2
100	Liver kinase B1 rs9282860 polymorphism and risk for multiple sclerosis in White and Black Americans. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103185.	0.9	3
101	Prognostic factors of disability in relapsing remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 9-16.	0.9	52
102	Racial and Ethnic Differences in Individuals with Sporadic Creutzfeldt-Jakob Disease in the United States of America. <i>PLoS ONE</i> , 2012, 7, e38884.	1.1	7
103	Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-182.	1.3	14
104	Muscle Dysfunction and Walking Impairment in Women with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2019, 21, 249-256.	0.4	14
105	Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis. <i>Biomolecules</i> , 2021, 11, 1510.	1.8	19
106	Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US. <i>JAMA Neurology</i> , 2021, 78, 1515.	4.5	68
107	What Could Be a Primary Cause of Multiple Sclerosis: Is It an Autoimmunity Triggered by Chronic Protozoan Infection?. <i>Journal of Neuroparasitology</i> , 2013, 4, 1-10.	0.6	1
108	Multiple Sclerosis; <i>Epidemiology</i> . , 2014, , 153-160.		0
109	Preliminary Study of Differences Between Prevalence of Multiple Sclerosis in Isfahan and itsâ€™ Rural Provinces. <i>Archives of Neuroscience</i> , 2015, 2, .	0.1	2
110	Epidemiology and Genetics. <i>Current Clinical Neurology</i> , 2020, , 71-87.	0.1	1

#	ARTICLE	IF	CITATIONS
111	Comparing the Workplace Discrimination Experiences of Older and Younger Workers With Multiple Sclerosis Under the Americans With Disabilities Act Amendments Act. <i>Journal of Applied Rehabilitation Counseling</i> , 2020, 51, 168-179.	0.0	0
112	Differences in Cardiometabolic Comorbidities Between Black and White Persons Living With Multiple Sclerosis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2022, 103, 331-335.	0.5	1
113	The Evaluation of Multiple Sclerosis Dispersal in Iran and Its Association with Urbanization, Life Style and Industry. <i>Iranian Journal of Public Health</i> , 2015, 44, 830-8.	0.3	22
114	Multidisciplinary Management of a Patient With Multiple Sclerosis: Part 1. Neurologists' and Psychiatrists' Perspectives. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2015, 32, 14S-17S.	0.6	0
115	The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2020, 37, S18-S23.	0.6	2
116	Non-White Participants Matter in White Matter Disease Studies. <i>Neurology</i> , 2022, 98, 345-346.	1.5	4
117	Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs. <i>Neurology</i> , 2022, 98, .	1.5	28
118	Quality of Life in Multiple Sclerosis Patients: Influence of Gender, Age and Marital Status. <i>Materia Socio-medica</i> , 2022, 34, 19.	0.3	8
119	MS Trials Continue to Under-Report, Under-Represent Non-White Participants. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2022, 22, 12-13.	0.0	0
120	The impact of post-traumatic stress on quality of life and fatigue in women with Gulf War Illness. <i>BMC Psychology</i> , 2022, 10, 42.	0.9	5
121	Association of pregnancies with risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1630-1640.	1.4	2
122	Factors associated with requesting accommodations among people with multiple sclerosis. <i>Work</i> , 2022, 71, 1051-1061.	0.6	1
123	A Systematic Review of Tissue and Single Cell Transcriptome/Proteome Studies of the Brain in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 761225.	2.2	6
124	The role of sex and pregnancy in multiple sclerosis: what do we know and what should we do?. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 377-392.	1.4	2
126	Prevalence of multiple sclerosis and treatment utilization in a large, highly diverse population. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103784.	0.9	1
127	The Impact of <i>CYP2C9*11</i> Allelic Variant on the Pharmacokinetics of Phenytoin and <i>S-warfarin</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 156-163.	2.3	5
128	Multiple Sclerosis Incidence in Black Patients. <i>Neurology</i> , 2022, 98, 739-740.	1.5	2
129	Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. <i>Neurology</i> , 2022, 98, .	1.5	48

#	ARTICLE	IF	CITATIONS
130	Variation of genes encoding nitric oxide synthases and antioxidant enzymes as potential risks of multiple sclerosis development: a preliminary study. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
131	Optic neuritis: A South African hospital-based prospective study protocol. <i>PLoS ONE</i> , 2022, 17, e0269514.	1.1	0
132	FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis. <i>BMJ Open</i> , 2022, 12, e058506.	0.8	5
133	Burden of neurological disease. , 2023, , 1047-1064.		0
134	Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon $\beta$ -1a phase 1 study. <i>Med</i> , 2022, , .	2.2	0
135	Genetics of multiple sclerosis: lessons from polygenicity. <i>Lancet Neurology</i> , The, 2022, 21, 830-842.	4.9	26
136	Towards a global view of multiple sclerosis genetics. <i>Nature Reviews Neurology</i> , 2022, 18, 613-623.	4.9	9
137	Pathogenesis and management of multiple sclerosis revisited. <i>Disease-a-Month</i> , 2023, 69, 101497.	0.4	3
138	Social determinants of health in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2022, 18, 723-734.	4.9	28
139	Examination of Ligand-Receptor Interactions amongst Different Multiple Sclerosis Lesion Types. <i>SunText Review of Neuroscience &amp; Psychology</i> , 2022, 03, .	0.0	0
140	An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis. <i>Cureus</i> , 2023, , .	0.2	4
141	Differential DNA methylation associated with multiple sclerosis and disease modifying treatments in an underrepresented minority population. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
142	Neuroimmunological Disorders. <i>Neurologic Clinics</i> , 2023, 41, 315-330.	0.8	2
143	Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. <i>Nature Reviews Neurology</i> , 2023, 19, 160-171.	4.9	48
144	Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
146	Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	8
147	The Pathological Activation of Microglia Is Modulated by Sexually Dimorphic Pathways. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4739.	1.8	2
148	Multiple sclerosis in Indigenous Peoples of the Americas: A systematic review of incidence, prevalence, and outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 72, 104612.	0.9	1

#	ARTICLE	IF	CITATIONS
149	A case-control study of drinking beverages and the risk of multiple sclerosis in Iran. Journal of Health, Population and Nutrition, 2023, 42, .	0.7	1
150	Health Disparities in Multiple Sclerosis among Hispanic and Black Populations in the United States. Biomedicines, 2023, 11, 1227.	1.4	2
162	Vitamin D and the epidemiology of multiple sclerosis. , 2024, , 1167-1184.		0